Eidos Therapeutics Inc (EIDX)


Stock Price Forecast

Jan. 25, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Eidos Therapeutics Inc chart...

About the Company

We do not have any company description for Eidos Therapeutics Inc at the moment.

Please visit http://eidostx.com for more information about the company.

CEO

Neil Kumar

Exchange

NASDAQ/NGS (GLOBAL SELECT MARKET)

Website

http://eidostx.com

$0M

Total Revenue

45

Employees

$5B

Market Capitalization

-46.12

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $EIDX News

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

13d ago, source: Zacks.com on MSN

The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Acoramidis is ...

Bayer purchases heart drug for up to $310 million

15d ago, source:

Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to ...

Bayer acquires exclusive marketing rights for acoramidis in Europe from Eidos & BridgeBio

13d ago, source: Pharmabiz

Bayer has acquired the exclusive marketing rights for acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Acoramidis is a highly potent and ...

Ovid Therapeutics Inc OVID

12h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

Kintara Therapeutics Inc KTRA

16h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Bayer purchases heart drug for up to $310 mln

15d ago, source: Reuters

The German drugmaker said it struck the deal with Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. The drug acoramidis is under review to treat a progressive hear ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...